patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_186397 | REC_0012501 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.9 | 67 | female | 0 | 7 | 5.7 | 6 | sotorasib 960 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.999707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958706 | REC_0012502 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 19.9 | 83 | female | 2 | 10 | 6.9 | 2 | osimertinib 80 mg daily | 34.6 | true | MSI-H | 2026-03-15T05:36:00.000028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855091 | REC_0012503 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.1 | 78 | female | 2 | 12 | 4.6 | 2 | alectinib 600 mg BID | 16.9 | false | MSS | 2026-03-15T05:36:00.000469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141973 | REC_0012504 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.8 | 57 | female | 1 | 14 | 6.5 | 5 | osimertinib 80 mg daily | 4.5 | true | MSS | 2026-03-15T05:36:00.000868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959337 | REC_0012505 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 8 | 63 | male | 1 | 16 | 4.9 | 5 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:00.001231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506088 | REC_0012506 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 5.8 | 63 | female | 0 | 19 | 5 | 2 | sotorasib 960 mg daily | 26.7 | false | MSS | 2026-03-15T05:36:00.001554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954612 | REC_0012507 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.6 | 74 | female | 3 | 21 | 5.5 | 3 | sotorasib 960 mg daily | 7 | true | MSS | 2026-03-15T05:36:00.002048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709278 | REC_0012508 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.5 | 69 | female | 0 | 35 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:36:00.002412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223435 | REC_0012509 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 65 | male | 0 | 16 | 7.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:36:00.002733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915827 | REC_0012510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.5 | 69 | female | 1 | 19 | 5.4 | 1 | osimertinib 80 mg daily | 13.5 | true | MSS | 2026-03-15T05:36:00.003063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752725 | REC_0012511 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 14.2 | 73 | female | 1 | 24 | 5.1 | 6 | sotorasib 960 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:00.003401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360206 | REC_0012512 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 11.7 | 80 | female | 0 | 18 | 5.6 | 1 | alectinib 600 mg BID | 15.9 | false | MSS | 2026-03-15T05:36:00.003715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132778 | REC_0012513 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.1 | 64 | female | 0 | 22 | 3.7 | 1 | alectinib 600 mg BID | 19.1 | false | MSI-H | 2026-03-15T05:36:00.004047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417019 | REC_0012514 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 15.5 | 56 | female | 0 | 17 | 6.2 | 0 | entrectinib 600 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:00.004546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174087 | REC_0012515 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 11.1 | 58 | female | 1 | 7 | 5.3 | 0 | osimertinib 80 mg daily | 40.4 | true | MSI-H | 2026-03-15T05:36:00.004913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796463 | REC_0012516 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15.2 | 65 | female | 1 | 25 | 7.8 | 7 | osimertinib 80 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:36:00.005248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970857 | REC_0012517 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7.8 | 75 | female | 2 | 20 | 4 | 6 | osimertinib 80 mg daily | 17.3 | false | MSS | 2026-03-15T05:36:00.005585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922892 | REC_0012518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16.7 | 75 | female | 1 | 14 | 7.6 | 4 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:00.005919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466581 | REC_0012519 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.4 | 78 | male | 3 | 60 | 6.6 | 2 | pembrolizumab 200 mg q3w | 20.5 | false | MSS | 2026-03-15T05:36:00.006239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939188 | REC_0012520 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.1 | 57 | female | 1 | 70 | 6.6 | 1 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:00.006732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951362 | REC_0012521 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.9 | 75 | female | 1 | 40 | 3.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:36:00.007102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750347 | REC_0012522 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.9 | 56 | male | 0 | 9 | 6.4 | 2 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:36:00.007447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691119 | REC_0012523 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 6.7 | 48 | female | 0 | 15 | 3.5 | 5 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:00.007772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435974 | REC_0012524 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 14.9 | 73 | female | 1 | 6 | 5.2 | 2 | osimertinib 80 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:36:00.008153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735114 | REC_0012525 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 10.7 | 62 | female | 1 | 28 | 7.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | false | MSS | 2026-03-15T05:36:00.008522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245929 | REC_0012526 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.4 | 68 | male | 0 | 5 | 8.2 | 5 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.008862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826004 | REC_0012527 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 16.8 | 72 | female | 2 | 19 | 4.4 | 7 | pembrolizumab 200 mg q3w | 9.1 | false | MSI-H | 2026-03-15T05:36:00.009199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517822 | REC_0012528 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.6 | 73 | female | 0 | 12 | 6 | 6 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.009530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610292 | REC_0012529 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.2 | 77 | male | 1 | 10 | 5.2 | 6 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:36:00.009852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526375 | REC_0012530 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.1 | 52 | female | 0 | 41 | 3.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:36:00.010194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986952 | REC_0012531 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.6 | 77 | female | 1 | 14 | 3.8 | 6 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.010536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846381 | REC_0012532 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.3 | 58 | male | 0 | 5 | 6.1 | 8 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:00.010869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622629 | REC_0012533 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 18.4 | 71 | female | 4 | 14 | 7.1 | 2 | entrectinib 600 mg daily | 20.3 | false | MSI-H | 2026-03-15T05:36:00.011430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809128 | REC_0012534 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 5.6 | 68 | female | 0 | 18 | 4.1 | 2 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:36:00.011795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712575 | REC_0012535 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 4.4 | 69 | female | 1 | 7 | 6.4 | 6 | sotorasib 960 mg daily | 7.7 | true | MSS | 2026-03-15T05:36:00.012199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653716 | REC_0012536 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 5.5 | 61 | female | 0 | 10 | 5 | 5 | pembrolizumab 200 mg q3w | 15.3 | false | MSS | 2026-03-15T05:36:00.012613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546325 | REC_0012537 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9.3 | 78 | female | 1 | 12 | 5.6 | 2 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:36:00.012959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794847 | REC_0012538 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.3 | 68 | female | 0 | 6 | 6.5 | 8 | entrectinib 600 mg daily | 10.4 | false | MSS | 2026-03-15T05:36:00.013308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463357 | REC_0012539 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.3 | 84 | female | 2 | 63 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:36:00.013682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392519 | REC_0012540 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.4 | 60 | male | 0 | 15 | 6.9 | 4 | entrectinib 600 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:36:00.014052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862177 | REC_0012541 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.8 | 65 | male | 1 | 38 | 3.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.8 | false | MSS | 2026-03-15T05:36:00.014414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878379 | REC_0012542 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 9 | 80 | female | 2 | 27 | 8.7 | 2 | pembrolizumab 200 mg q3w | 22.2 | false | MSS | 2026-03-15T05:36:00.014785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534232 | REC_0012543 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 9.2 | 58 | male | 1 | 12 | 5 | 3 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:00.015186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407938 | REC_0012544 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 15.7 | 68 | female | 1 | 10 | 6.2 | 2 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:36:00.015592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890179 | REC_0012545 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 6.3 | 64 | female | 0 | 22 | 4.4 | 1 | sotorasib 960 mg daily | 26 | false | MSS | 2026-03-15T05:36:00.015946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302859 | REC_0012546 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 8.5 | 81 | male | 1 | 0 | 6.8 | 6 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:36:00.016584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221027 | REC_0012547 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 12.7 | 63 | female | 1 | 11 | 5.1 | 5 | pembrolizumab 200 mg q3w | 16.5 | true | MSI-H | 2026-03-15T05:36:00.017018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190496 | REC_0012548 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 10.8 | 67 | female | 1 | 20 | 5.5 | 0 | osimertinib 80 mg daily | 31.3 | true | MSS | 2026-03-15T05:36:00.017415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167079 | REC_0012549 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 7.7 | 65 | male | 1 | 1 | 3 | 7 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:00.017799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183009 | REC_0012550 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14.1 | 68 | female | 1 | 5 | 4.6 | 4 | osimertinib 80 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:36:00.018174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882667 | REC_0012551 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 17.4 | 81 | female | 2 | 13 | 4.5 | 0 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:00.018543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640847 | REC_0012552 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.2 | 69 | female | 1 | 11 | 3.7 | 4 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:00.018914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543454 | REC_0012553 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.8 | 56 | female | 0 | 48 | 3.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.6 | false | MSS | 2026-03-15T05:36:00.019286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256383 | REC_0012554 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.8 | 68 | female | 0 | 16 | 7.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:00.019660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403630 | REC_0012555 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.4 | 80 | female | 1 | 1 | 4.4 | 6 | alectinib 600 mg BID | 10.5 | true | MSI-H | 2026-03-15T05:36:00.020034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324406 | REC_0012556 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.6 | 67 | male | 0 | 35 | 7.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.9 | true | MSS | 2026-03-15T05:36:00.020884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377576 | REC_0012557 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7.2 | 56 | female | 1 | 11 | 6.4 | 5 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:36:00.021317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543424 | REC_0012558 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 8 | 59 | male | 1 | 8 | 5.6 | 7 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:00.021675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664670 | REC_0012559 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.8 | 80 | female | 1 | 38 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:00.022256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987361 | REC_0012560 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.8 | 71 | male | 1 | 40 | 7.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:36:00.022682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379425 | REC_0012561 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.2 | 68 | female | 1 | 22 | 2.6 | 7 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:00.023070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951193 | REC_0012562 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10.8 | 61 | male | 0 | 9 | 6.2 | 5 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:00.023472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122452 | REC_0012563 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 4.7 | 53 | male | 0 | 30 | 5.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 18.9 | true | MSS | 2026-03-15T05:36:00.025679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655606 | REC_0012564 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 17.9 | 66 | female | 0 | 25 | 5.2 | 4 | sotorasib 960 mg daily | 4.3 | false | MSS | 2026-03-15T05:36:00.026147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239944 | REC_0012565 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.2 | 68 | male | 0 | 12 | 6.6 | 1 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:36:00.026512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299201 | REC_0012566 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 2.5 | 69 | female | 1 | 58 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:00.026822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314995 | REC_0012567 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10 | 74 | male | 2 | 19 | 4.6 | 3 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:36:00.027143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319815 | REC_0012568 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.1 | 73 | male | 3 | 19 | 5.4 | 6 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:36:00.027472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415993 | REC_0012569 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.2 | 62 | male | 0 | 21 | 7.5 | 9 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:36:00.027804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620212 | REC_0012570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 6.3 | 55 | male | 0 | 19 | 6.2 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.028214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550333 | REC_0012571 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 14.5 | 71 | male | 2 | 4 | 6 | 2 | osimertinib 80 mg daily | 22.6 | true | MSI-H | 2026-03-15T05:36:00.028633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650506 | REC_0012572 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 67 | female | 0 | 43 | 7.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:36:00.029193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399834 | REC_0012573 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.9 | 65 | female | 0 | 8 | 5.6 | 6 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:00.029568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399295 | REC_0012574 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 4.7 | 63 | female | 1 | 57 | 8.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:36:00.029879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971994 | REC_0012575 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 5.5 | 89 | female | 1 | 20 | 3.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:36:00.030235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314487 | REC_0012576 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.8 | 67 | female | 0 | 23 | 6.2 | 5 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:36:00.030614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947828 | REC_0012577 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7 | 72 | male | 1 | 7 | 5.1 | 3 | osimertinib 80 mg daily | 29.5 | false | MSS | 2026-03-15T05:36:00.030965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118606 | REC_0012578 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.3 | 60 | male | 0 | 11 | 5.9 | 1 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:00.031344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559348 | REC_0012579 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 8.8 | 57 | male | 1 | 2 | 6.6 | 4 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:36:00.031721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516302 | REC_0012580 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 10.1 | 70 | male | 2 | 24 | 7.9 | 2 | osimertinib 80 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:36:00.032576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558940 | REC_0012581 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 20 | 9.8 | 56 | female | 0 | 13 | 6.2 | 0 | pembrolizumab 200 mg q3w | 38.4 | false | MSS | 2026-03-15T05:36:00.033080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791084 | REC_0012582 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.8 | 73 | male | 0 | 7 | 4.8 | 4 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:00.033436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457183 | REC_0012583 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 5.2 | 65 | male | 1 | 45 | 5.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:36:00.033775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382347 | REC_0012584 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.7 | 73 | female | 2 | 21 | 4.9 | 6 | sotorasib 960 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:36:00.034115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122855 | REC_0012585 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 6.8 | 73 | male | 1 | 30 | 7.7 | 5 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:36:00.034643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312928 | REC_0012586 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.5 | 64 | female | 1 | 5 | 4.2 | 1 | osimertinib 80 mg daily | 27.9 | false | MSS | 2026-03-15T05:36:00.035032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774939 | REC_0012587 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 12 | 73 | male | 2 | 19 | 2.4 | 2 | pembrolizumab 200 mg q3w | 27.9 | false | MSS | 2026-03-15T05:36:00.035371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988489 | REC_0012588 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 13 | 78 | female | 2 | 12 | 4.7 | 7 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:00.035692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980030 | REC_0012589 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 17.6 | 90 | male | 2 | 22 | 6.4 | 3 | alectinib 600 mg BID | 15.5 | false | MSI-H | 2026-03-15T05:36:00.036003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155709 | REC_0012590 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.8 | 67 | female | 0 | 14 | 5.5 | 5 | sotorasib 960 mg daily | 19.2 | false | MSS | 2026-03-15T05:36:00.036513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153742 | REC_0012591 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 8.9 | 84 | female | 1 | 12 | 6.8 | 5 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:36:00.036882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408244 | REC_0012592 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6.2 | 81 | female | 0 | 8 | 4.2 | 6 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:00.037249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359829 | REC_0012593 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 13.3 | 68 | male | 1 | 5 | 6.8 | 6 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.037651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366127 | REC_0012594 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 12.2 | 87 | male | 1 | 17 | 6.2 | 1 | alectinib 600 mg BID | 22.3 | true | MSS | 2026-03-15T05:36:00.038042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880364 | REC_0012595 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 17.9 | 67 | female | 1 | 10 | 4.5 | 1 | entrectinib 600 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:36:00.038416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554480 | REC_0012596 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 4.8 | 69 | female | 1 | 21 | 6.1 | 1 | sotorasib 960 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.038769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719826 | REC_0012597 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 6.6 | 67 | female | 1 | 27 | 7 | 0 | carboplatin + paclitaxel + pembrolizumab | 24.7 | true | MSS | 2026-03-15T05:36:00.039143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790597 | REC_0012598 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 13.1 | 71 | female | 2 | 9 | 7.4 | 1 | alectinib 600 mg BID | 22.1 | false | MSI-H | 2026-03-15T05:36:00.039704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758762 | REC_0012599 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.2 | 72 | male | 2 | 15 | 6.2 | 2 | alectinib 600 mg BID | 20.9 | true | MSS | 2026-03-15T05:36:00.040208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623014 | REC_0012600 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.7 | 72 | female | 1 | 66 | 4.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:36:00.040643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.